Key result
The novel Nanobody-based 3ABC competitive ELISA demonstrated high diagnostic sensitivity of 94% and specificity of 97.67% for detecting FMD non-structural protein antibodies in cattle.
Why the study?
Does a novel Nanobody-based FMD 3ABC competitive ELISA accurately detect FMD NSP antibodies in cattle sera?
Observational (n=631)
Does a novel Nanobody-based FMD 3ABC competitive ELISA accurately detect FMD NSP antibodies in cattle sera?
Effect estimate: Sensitivity 94% (95% CI 88.9-97.2)
A novel Nanobody-based competitive ELISA demonstrated high sensitivity and specificity for detecting FMD NSP antibodies in cattle, offering a potentially cost-effective diagnostic tool for endemic regions.
May support affordable FMD surveillance in cattle; leaves open field validation before routine adoption.
Effective management of foot and mouth disease (FMD) requires diagnostic tests to distinguish between infected and vaccinated animals (DIVA). To address this need, several enzyme-linked immunosorbent assay (ELISA) platforms have been developed, however, these tests vary in their sensitivity and specificity and are very expensive for developing countries. Camelid-derived single-domain antibodies fragments so-called Nanobodies, have demonstrated great efficacy for the development of serological diagnostics. This study describes the development of a novel Nanobody-based FMD 3ABC competitive ELISA, for the serological detection of antibodies against FMD Non-Structural Proteins (NSP) in Uganda cattle herds. This in-house ELISA was validated using more than 600 sera from different Uganda districts, and virus serotype specificities. The evaluation of the performance of the assay demonstrated high diagnostic sensitivity and specificity of 94 % (95 % CI: 88.9-97.2), and 97.67 % (95 % CI: 94.15-99.36) respectively, as well as the capability to detect NSP-specific antibodies against multiple FMD serotype infections. In comparison with the commercial PrioCHECK FMDV NSP-FMD test, there was a strong concordance and high correlation and agreement in the performance of the two tests. This new developed Nanobody based FMD 3ABC competitive ELISA could clearly benefit routine disease diagnosis, the establishment of disease-free zones, and the improvement of FMD management and control in endemically complex environments, such as those found in Africa.
No takes yet. Share an insight, caveat, or question.
Gelkop et al. (2018) conducted an observational in Foot and Mouth Disease (n=631). Nanobody-based 3ABC competitive ELISA vs. PrioCHECK FMDV NSP test was evaluated on Diagnostic sensitivity (Sensitivity 94%, 95% CI 88.9-97.2). The novel Nanobody-based 3ABC competitive ELISA demonstrated high diagnostic sensitivity of 94% and specificity of 97.67% for detecting FMD non-structural protein antibodies in cattle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: